Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (11-20 of 287) with videos related to

Pageof 29
Sort By:
Minerva Pediatrica|October 31, 1984
[Prolactin response to TRH in patients with idiopathic delayed puberty]R Mauri, M Resentini, P Lissoni, et al.
Tumori|October 31, 1989
Evidence for altered hypothalamic-hypophyseal-gonadal axis in untreated patients with testicular germ-cell tumorS Crispino, G Tancini, S Barni, et al.
The International Journal of Biological Markers|January 1, 1989
Prolactin secretion in testicular cancer patientsP Lissoni, S Crispino, S Barni, et al.
Oncology|January 1, 1991
Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary reportP Lissoni, S Barni, F Rovelli, et al.
The International Journal of Biological Markers|July 10, 1999
Changes in lymphocyte number during cancer chemotherapy and their relation to clinical responseP Lissoni, L Fumagalli, F Paolorossi, et al.
Anticancer Research|August 6, 2000
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignanciesP Lissoni, S Bolis, F Brivio, et al.
Oncology Reports|May 19, 2011
Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomasP Lissoni, S Barni, A Ardizzoia, et al.
The International Journal of Biological Markers|April 1, 1997
Interleukin-4 blood concentrations in early and metastatic human solid neoplasmsP Lissoni, D Merlini, D Pirato, et al.
Journal of Biological Regulators and Homeostatic Agents|September 30, 1999
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?P Lissoni, F Brivio, S Viviani, et al.
The International Journal of Biological Markers|January 1, 1995
Effects of granulocyte colony stimulating factor on the specific macrophage marker neopterin in cancer patientsP Lissoni, S Barni, M G Grassi, et al.
Pageof 29

Showing results (11-20 of 287) with videos related to

Sort By:
Pageof 29
Minerva Pediatrica|October 31, 1984
[Prolactin response to TRH in patients with idiopathic delayed puberty]R Mauri, M Resentini, P Lissoni, et al.
Tumori|October 31, 1989
Evidence for altered hypothalamic-hypophyseal-gonadal axis in untreated patients with testicular germ-cell tumorS Crispino, G Tancini, S Barni, et al.
The International Journal of Biological Markers|January 1, 1989
Prolactin secretion in testicular cancer patientsP Lissoni, S Crispino, S Barni, et al.
Oncology|January 1, 1991
Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary reportP Lissoni, S Barni, F Rovelli, et al.
The International Journal of Biological Markers|July 10, 1999
Changes in lymphocyte number during cancer chemotherapy and their relation to clinical responseP Lissoni, L Fumagalli, F Paolorossi, et al.
Anticancer Research|August 6, 2000
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignanciesP Lissoni, S Bolis, F Brivio, et al.
Oncology Reports|May 19, 2011
Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomasP Lissoni, S Barni, A Ardizzoia, et al.
The International Journal of Biological Markers|April 1, 1997
Interleukin-4 blood concentrations in early and metastatic human solid neoplasmsP Lissoni, D Merlini, D Pirato, et al.
Journal of Biological Regulators and Homeostatic Agents|September 30, 1999
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?P Lissoni, F Brivio, S Viviani, et al.
The International Journal of Biological Markers|January 1, 1995
Effects of granulocyte colony stimulating factor on the specific macrophage marker neopterin in cancer patientsP Lissoni, S Barni, M G Grassi, et al.
Pageof 29